At the American Association for Cancer Research's annual meeting in Chicago last week, the Novartis Institute for BioMedical Research's William Sellers spoke about the importance of finding the right combinations of drugs to treat different kinds of cancer. "One drug is never enough," he said during his talk at the opening plenary session.
Finding the right combinations can be "daunting," he added. But companies like Novartis are developing ways to make the process more efficient. Sellers showed a short clip of a high-throughput robotic system that he says can test 1,500 compounds on 600 different cancer cell lines in just three months, in order to see if these compounds have any therapeutic effect.
(Video courtesy of William Sellers)